LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 476

Search options

  1. Article ; Online: Interview: interview with P Jeffrey Conn. Interview by Hannah Coaker.

    Conn, P Jeffrey

    Future medicinal chemistry

    2013  Volume 5, Issue 13, Page(s) 1483–1489

    Abstract: Dr Conn is the Lee E Limbird Professor of Pharmacology at Vanderbilt University and Director ... of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD). Dr Conn received a PhD in Pharmacology ... of the Department of Neuroscience. Dr Conn moved to Vanderbilt University in 2003 where he is the founding director ...

    Abstract Dr Conn is the Lee E Limbird Professor of Pharmacology at Vanderbilt University and Director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD). Dr Conn received a PhD in Pharmacology from Vanderbilt in 1986 and pursued postdoctoral studies at Yale University. He served as a professor of Pharmacology at Emory University from 1988 to 2000, before moving to Merck and Co. (PA, USA) as head of the Department of Neuroscience. Dr Conn moved to Vanderbilt University in 2003 where he is the founding director of the VCNDD, with a primary mission of facilitating translation of recent advances in basic science to novel therapeutics. The VCNDD consists of approximately 100 full-time scientists and has advanced novel molecules from four major programs as development candidates for clinical testing with industry partners. Dr Conn has served in editorial positions with multiple international journals and has served the scientific advisory boards of multiple foundations and companies. He has received numerous awards based on the impact of his basic and translational research. Dr Conn's current research is focused on development of novel treatment strategies for schizophrenia, Parkinson's disease and other serious brain disorders. Interview conducted by Hannah Coaker, Assistant Commissioning Editor.
    MeSH term(s) Animals ; Drug Discovery/methods ; Drug Discovery/organization & administration ; Humans ; Mental Disorders/drug therapy ; Mental Disorders/metabolism ; Models, Animal ; Nervous System Diseases/drug therapy ; Nervous System Diseases/metabolism ; Neurosciences/methods ; Neurosciences/organization & administration ; Schizophrenia/drug therapy ; Schizophrenia/metabolism ; Translational Medical Research
    Language English
    Publishing date 2013-09-11
    Publishing country England
    Document type Interview ; Research Support, Non-U.S. Gov't
    ISSN 1756-8927
    ISSN (online) 1756-8927
    DOI 10.4155/fmc.13.120
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: An interview with P. Jeffrey Conn.

    Conn, P Jeffrey

    Trends in pharmacological sciences

    2012  Volume 33, Issue 3, Page(s) 119–121

    MeSH term(s) Humans ; Mental Disorders/drug therapy ; Nervous System Diseases/drug therapy ; Pharmacology
    Language English
    Publishing date 2012-04-04
    Publishing country England
    Document type Interview
    ZDB-ID 282846-7
    ISSN 1873-3735 ; 0165-6147
    ISSN (online) 1873-3735
    ISSN 0165-6147
    DOI 10.1016/j.tips.2012.01.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Book ; Online ; E-Book: Conn's handbook of models for human aging

    Conn, Michael P. / Ram, Jeffrey L.

    2018  

    Title variant Handbook of models for human aging ; Models for human aging
    Author's details edited by Jeffrey L. Ram, P. Michael Conn
    Language English
    Size 1 Online-Ressource (xx, 1197 Seiten), Illustrationen
    Edition Second edition
    Publisher Elsevier Academic Press
    Publishing place London
    Publishing country Great Britain
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT019684660
    ISBN 978-0-12-811354-7 ; 9780128113530 ; 0-12-811354-5 ; 0128113537
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  4. Article ; Online: Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.

    Dogra, Shalini / Conn, P Jeffrey

    Molecular pharmacology

    2022  Volume 101, Issue 5, Page(s) 275–285

    Abstract: Accumulating evidence of glutamatergic abnormalities in the brains of schizophrenia patients has led to efforts to target various components of glutamatergic signaling as potential new approaches for schizophrenia. Exciting research suggests that ... ...

    Abstract Accumulating evidence of glutamatergic abnormalities in the brains of schizophrenia patients has led to efforts to target various components of glutamatergic signaling as potential new approaches for schizophrenia. Exciting research suggests that metabotropic glutamate (mGlu) receptors could provide a fundamentally new approach for better symptomatic relief in patients with schizophrenia. In preclinical studies, the mGlu
    MeSH term(s) Allosteric Regulation ; Animals ; Antipsychotic Agents/pharmacology ; Antipsychotic Agents/therapeutic use ; Glutamic Acid ; Humans ; Receptor, Metabotropic Glutamate 5/metabolism ; Receptors, N-Methyl-D-Aspartate/metabolism ; Schizophrenia/drug therapy
    Chemical Substances Antipsychotic Agents ; Receptor, Metabotropic Glutamate 5 ; Receptors, N-Methyl-D-Aspartate ; Glutamic Acid (3KX376GY7L)
    Language English
    Publishing date 2022-03-03
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, N.I.H., Extramural
    ZDB-ID 124034-1
    ISSN 1521-0111 ; 0026-895X
    ISSN (online) 1521-0111
    ISSN 0026-895X
    DOI 10.1124/molpharm.121.000460
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease.

    Luessen, Deborah J / Conn, P Jeffrey

    Pharmacological reviews

    2022  Volume 74, Issue 3, Page(s) 630–661

    Abstract: Metabotropic glutamate (mGlu) receptors, a family of G-protein-coupled receptors, have been identified as novel therapeutic targets based on extensive research supporting their diverse contributions to cell signaling and physiology throughout the nervous ...

    Abstract Metabotropic glutamate (mGlu) receptors, a family of G-protein-coupled receptors, have been identified as novel therapeutic targets based on extensive research supporting their diverse contributions to cell signaling and physiology throughout the nervous system and important roles in regulating complex behaviors, such as cognition, reward, and movement. Thus, targeting mGlu receptors may be a promising strategy for the treatment of several brain disorders. Ongoing advances in the discovery of subtype-selective allosteric modulators for mGlu receptors has provided an unprecedented opportunity for highly specific modulation of signaling by individual mGlu receptor subtypes in the brain by targeting sites distinct from orthosteric or endogenous ligand binding sites on mGlu receptors. These pharmacological agents provide the unparalleled opportunity to selectively regulate neuronal excitability, synaptic transmission, and subsequent behavioral output pertinent to many brain disorders. Here, we review preclinical and clinical evidence supporting the utility of mGlu receptor allosteric modulators as novel therapeutic approaches to treat neuropsychiatric diseases, such as schizophrenia, substance use disorders, and stress-related disorders. SIGNIFICANCE STATEMENT: Allosteric modulation of metabotropic glutamate (mGlu) receptors represents a promising therapeutic strategy to normalize dysregulated cellular physiology associated with neuropsychiatric disease. This review summarizes preclinical and clinical studies using mGlu receptor allosteric modulators as experimental tools and potential therapeutic approaches for the treatment of neuropsychiatric diseases, including schizophrenia, stress, and substance use disorders.
    MeSH term(s) Allosteric Regulation/physiology ; Binding Sites ; Brain Diseases ; Glutamic Acid ; Humans ; Receptors, Metabotropic Glutamate/chemistry ; Receptors, Metabotropic Glutamate/metabolism
    Chemical Substances Receptors, Metabotropic Glutamate ; Glutamic Acid (3KX376GY7L)
    Language English
    Publishing date 2022-06-13
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 209898-2
    ISSN 1521-0081 ; 0031-6997
    ISSN (online) 1521-0081
    ISSN 0031-6997
    DOI 10.1124/pharmrev.121.000540
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.

    Dogra, Shalini / Conn, P Jeffrey

    Neuropharmacology

    2021  Volume 196, Page(s) 108687

    Abstract: The discovery of robust antidepressant effects of ketamine in refractory patients has led to increasing focus on agents targeting glutamatergic signaling as potential novel antidepressant strategy. Among the agents targeting the glutamatergic system, ... ...

    Abstract The discovery of robust antidepressant effects of ketamine in refractory patients has led to increasing focus on agents targeting glutamatergic signaling as potential novel antidepressant strategy. Among the agents targeting the glutamatergic system, compounds acting at metabotropic glutamate (mGlu) receptors are among the most promising agents under studies for depressive disorders. Further, the receptor diversity, distinct distribution in the CNS, and ability to modulate the glutamatergic neurotransmission in the brain areas implicated in mood disorders make them an exciting target for stress-related disorders. In preclinical models, antidepressant and anxiolytic effects of mGlu
    MeSH term(s) Allosteric Regulation ; Animals ; Anxiety Disorders/drug therapy ; Brain/metabolism ; Depressive Disorder, Major/drug therapy ; Depressive Disorder, Treatment-Resistant/drug therapy ; Excitatory Amino Acid Antagonists/therapeutic use ; Humans ; Ketamine/therapeutic use ; Molecular Targeted Therapy ; Receptor, Metabotropic Glutamate 5/antagonists & inhibitors ; Receptors, Metabotropic Glutamate/antagonists & inhibitors ; Stress, Psychological/drug therapy
    Chemical Substances Excitatory Amino Acid Antagonists ; Receptor, Metabotropic Glutamate 5 ; Receptors, Metabotropic Glutamate ; metabotropic glutamate receptor 2 ; metabotropic glutamate receptor 3 ; metabotropic glutamate receptor type 1 ; Ketamine (690G0D6V8H)
    Language English
    Publishing date 2021-06-25
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 218272-5
    ISSN 1873-7064 ; 0028-3908
    ISSN (online) 1873-7064
    ISSN 0028-3908
    DOI 10.1016/j.neuropharm.2021.108687
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Leveraging bias to your advantage.

    Moran, Sean P / Conn, P Jeffrey

    Nature chemical biology

    2020  Volume 16, Issue 3, Page(s) 226–227

    MeSH term(s) Animals ; Cholinergic Agents ; Mice ; Receptor, Muscarinic M1
    Chemical Substances Cholinergic Agents ; Receptor, Muscarinic M1
    Language English
    Publishing date 2020-02-17
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2202962-X
    ISSN 1552-4469 ; 1552-4450
    ISSN (online) 1552-4469
    ISSN 1552-4450
    DOI 10.1038/s41589-020-0468-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Targeting the Actions of Muscarinic Receptors on Dopamine Systems: New Strategies for Treating Neuropsychiatric Disorders.

    Nunes, Eric J / Addy, Nii A / Conn, P Jeffrey / Foster, Daniel J

    Annual review of pharmacology and toxicology

    2023  Volume 64, Page(s) 277–289

    Abstract: Cholinergic regulation of dopamine (DA) signaling has significant implications for numerous disorders, including schizophrenia, substance use disorders, and mood-related disorders. The activity of midbrain DA neurons and DA release patterns in terminal ... ...

    Abstract Cholinergic regulation of dopamine (DA) signaling has significant implications for numerous disorders, including schizophrenia, substance use disorders, and mood-related disorders. The activity of midbrain DA neurons and DA release patterns in terminal regions are tightly regulated by cholinergic neurons found in both the striatum and the hindbrain. These cholinergic neurons can modulate DA circuitry by activating numerous receptors, including muscarinic acetylcholine receptor (mAChR) subtypes. This review specifically focuses on the complex role of M2, M4, and M5 mAChR subtypes in regulating DA neuron activity and DA release and the potential clinical implications of targeting these mAChR subtypes.
    MeSH term(s) Humans ; Dopamine ; Receptors, Muscarinic/metabolism ; Corpus Striatum/metabolism ; Signal Transduction
    Chemical Substances Dopamine (VTD58H1Z2X) ; Receptors, Muscarinic
    Language English
    Publishing date 2023-08-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 196587-6
    ISSN 1545-4304 ; 0362-1642
    ISSN (online) 1545-4304
    ISSN 0362-1642
    DOI 10.1146/annurev-pharmtox-051921-023858
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders.

    Dogra, Shalini / Putnam, Jason / Conn, P Jeffrey

    Pharmacology, biochemistry, and behavior

    2022  Volume 221, Page(s) 173493

    Abstract: Glutamate is a major excitatory neurotransmitter in the central nervous system (CNS) and abnormalities in the glutamatergic system underlie various CNS disorders. As metabotropic glutamate receptor 3 ( ... ...

    Abstract Glutamate is a major excitatory neurotransmitter in the central nervous system (CNS) and abnormalities in the glutamatergic system underlie various CNS disorders. As metabotropic glutamate receptor 3 (mGlu
    MeSH term(s) Humans ; Receptors, Metabotropic Glutamate ; Nervous System Diseases/drug therapy ; Central Nervous System ; Glutamic Acid
    Chemical Substances metabotropic glutamate receptor 3 ; Receptors, Metabotropic Glutamate ; Glutamic Acid (3KX376GY7L)
    Language English
    Publishing date 2022-11-17
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, N.I.H., Extramural
    ZDB-ID 191042-5
    ISSN 1873-5177 ; 0091-3057
    ISSN (online) 1873-5177
    ISSN 0091-3057
    DOI 10.1016/j.pbb.2022.173493
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors.

    Stansley, Branden J / Conn, P Jeffrey

    Trends in pharmacological sciences

    2019  Volume 40, Issue 4, Page(s) 240–252

    Abstract: The metabotropic glutamate (mGlu) receptors are a family of G-protein-coupled receptors (GPCRs) that regulate cell physiology throughout the nervous system. The potential of mGlu receptors as therapeutic targets has been bolstered by current research ... ...

    Abstract The metabotropic glutamate (mGlu) receptors are a family of G-protein-coupled receptors (GPCRs) that regulate cell physiology throughout the nervous system. The potential of mGlu receptors as therapeutic targets has been bolstered by current research that has provided insight into the diverse modes of mGlu activation and signaling. In particular, the allosteric modulation of mGlu receptors represents a major area of focus in studies of basic pharmacology as well as drug development, largely due to the high subtype specificity achievable by targeting allosteric sites on mGlu receptors. These provide sophisticated regulation of neuronal excitability and synaptic transmission to influence behavioral output. Here, we review how these allosteric mechanisms have been leveraged preclinically to demonstrate the therapeutic potential of allosteric modulators for neurological and neuropsychiatric disorders, such as autism, cognitive impairment, Parkinson's disease (PD), stress, and schizophrenia.
    MeSH term(s) Allosteric Regulation ; Allosteric Site ; Animals ; Drug Development ; Humans ; Mental Disorders/drug therapy ; Mental Disorders/physiopathology ; Receptors, Metabotropic Glutamate/drug effects ; Receptors, Metabotropic Glutamate/metabolism ; Synaptic Transmission
    Chemical Substances Receptors, Metabotropic Glutamate
    Language English
    Publishing date 2019-02-26
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 282846-7
    ISSN 1873-3735 ; 0165-6147
    ISSN (online) 1873-3735
    ISSN 0165-6147
    DOI 10.1016/j.tips.2019.02.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top